Potential Impact of the Bivalent RLP2806 Vaccine on Neisseria Meningitidis Carriage and Invasive Serogroup B Disease

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2012 Dec 20

PMID 23249817

Citations 8

Authors

Annaliesa S Anderson

Li Hao

Qin Jiang

Shannon L Harris

Thomas R Jones

John L Perez

Laura York

Joseph Eiden

Kathrin U Jansen

Affiliations

Soon will be listed here.

Abstract

Asymptomatic throat carriage of Neisseria meningitidis is common in healthy individuals. In unusual cases, the bacteria become invasive, resulting in life-threatening disease. Effective meningococcal serogroup B (MnB) vaccines should provide broad protection against disease-causing strains and may confer indirect protection by impacting carriage and subsequent transmission. Factor H binding proteins (fHBPs), components of MnB vaccines in development, are classified into two immunologically distinct subfamilies (A and B). fHBP variants of MnB strains carried by adolescents are similar to those detected in infants with MnB disease. A vaccine containing subfamily A and B fHBP variants elicited bactericidal antibody responses (titers ≥ 1:4) against MnB strains expressing fHBP variants common to carriage strains and strains that cause disease in adolescents and infants in 75-100% of adolescent study subjects. This suggests that the bivalent fHBP vaccine has the potential to provide protection against invasive MnB strains and interrupt meningococcal carriage, which may also reduce infant MnB disease.

Citing Articles

Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines.

Terranova L, Principi N, Bianchini S, Di Pietro G, Umbrello G, Madini B Hum Vaccin Immunother. 2018; 14(5):1070-1074.

PMID: 29584565 PMC: 5989914. DOI: 10.1080/21645515.2018.1450121.

MenB-FHbp Meningococcal Group B Vaccine (Trumenba): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

Shirley M, Taha M Drugs. 2018; 78(2):257-268.

PMID: 29380290 DOI: 10.1007/s40265-018-0869-7.

How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Gasparini R, Panatto D, Bragazzi N, Lai P, Bechini A, Levi M J Immunol Res. 2015; 2015:189153.

PMID: 26351643 PMC: 4553322. DOI: 10.1155/2015/189153.

Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Jones C, Mohamed N, Rojas E, Andrew L, Hoyos J, Hawkins J J Clin Microbiol. 2015; 54(1):25-34.

PMID: 26311858 PMC: 4702718. DOI: 10.1128/JCM.01447-15.

Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.

Gasparini R, Comanducci M, Amicizia D, Ansaldi F, Canepa P, Orsi A J Clin Microbiol. 2014; 52(6):1901-10.

PMID: 24648565 PMC: 4042792. DOI: 10.1128/JCM.03584-13.

References

Richmond P, Marshall H, Nissen M, Jiang Q, Jansen K, Garces-Sanchez M . Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012; 12(8):597-607. DOI: 10.1016/S1473-3099(12)70087-7. View

AlaAldeen D, Flint M, Oldfield N, Omer S, McNeil L, Jiang Q . Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine. 2010; 28(48):7667-75. DOI: 10.1016/j.vaccine.2010.09.038. View

Borrow R, Carlone G, Rosenstein N, Blake M, Feavers I, Martin D . Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006; 24(24):5093-107. DOI: 10.1016/j.vaccine.2006.03.091. View

Jounio U, Saukkoriipi A, Bratcher H, Bloigu A, Juvonen R, Silvennoinen-Kassinen S . Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol. 2011; 50(2):264-73. PMC: 3264188. DOI: 10.1128/JCM.05385-11. View

McNeil L, Murphy E, Zhao X, Guttmann S, Harris S, Scott A . Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009; 27(25-26):3417-21. DOI: 10.1016/j.vaccine.2009.01.075. View

Fletcher L, Bernfield L, Barniak V, Farley J, Howell A, Knauf M . Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004; 72(4):2088-100. PMC: 375149. DOI: 10.1128/IAI.72.4.2088-2100.2004. View

Murphy E, Andrew L, Lee K, Dilts D, Nunez L, Fink P . Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009; 200(3):379-89. DOI: 10.1086/600141. View

Pajon R, Beernink P, Harrison L, Granoff D . Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010; 28(9):2122-9. PMC: 2830318. DOI: 10.1016/j.vaccine.2009.12.027. View

Jiang H, Hoiseth S, Harris S, McNeil L, Zhu D, Tan C . Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010; 28(37):6086-93. DOI: 10.1016/j.vaccine.2010.06.083. View

10.

Yazdankhah S, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M . Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2004; 42(11):5146-53. PMC: 525265. DOI: 10.1128/JCM.42.11.5146-5153.2004. View

11.

Germinario C, Tafuri S, Napoli C, Montagna M, Balducci M, Fortunato F . Young-adult carriers of Neisseria meningitidis in Puglia (Italy): will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?. Hum Vaccin. 2010; 6(12):1025-7. DOI: 10.4161/hv.6.12.13145. View

12.

Masignani V, Comanducci M, Giuliani M, Bambini S, Adu-Bobie J, Arico B . Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003; 197(6):789-99. PMC: 2193853. DOI: 10.1084/jem.20021911. View

13.

Anderson A, Jansen K, Eiden J . New frontiers in meningococcal vaccines. Expert Rev Vaccines. 2011; 10(5):617-34. DOI: 10.1586/erv.11.50. View

14.

Schneider M, Exley R, Chan H, Feavers I, Kang Y, Sim R . Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006; 176(12):7566-75. DOI: 10.4049/jimmunol.176.12.7566. View

15.

Madico G, Welsch J, Lewis L, McNaughton A, Perlman D, Costello C . The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006; 177(1):501-10. PMC: 2248442. DOI: 10.4049/jimmunol.177.1.501. View

16.

Trotter C, Ramsay M . Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2006; 31(1):101-7. DOI: 10.1111/j.1574-6976.2006.00053.x. View

17.

Marsh J, Shutt K, Pajon R, Tulenko M, Liu S, Hollick R . Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine. 2011; 29(35):6049-58. PMC: 4762365. DOI: 10.1016/j.vaccine.2011.06.025. View

18.

Girard M, Preziosi M, Aguado M, Kieny M . A review of vaccine research and development: meningococcal disease. Vaccine. 2006; 24(22):4692-700. DOI: 10.1016/j.vaccine.2006.03.034. View

19.

. Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep. 2011; 58(53):1-100. View

20.

Ibarz-Pavon A, Lemos A, Gorla M, Regueira M, Gabastou J . Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. PLoS One. 2012; 7(8):e44102. PMC: 3431326. DOI: 10.1371/journal.pone.0044102. View